Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection

Journal of Bone and Mineral Research

Volumn 11, Issue 5, 1996, Pages 587-593

  Pecherstorfer, Martin ^a   Ludwig, Heinz ^a   Schlosser, Karl ^b   Buck, Signe ^a   Huss, Hermann Josef ^b   Body, Jean Jacques ^c  

^a WILHELMINEN HOSPITAL   (Austria)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CREATININE; FORMESTANE; IBANDRONIC ACID; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BOLUS INJECTION; BONE METASTASIS; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; IMPAIRED GLUCOSE TOLERANCE; INTRAVENOUS DRUG ADMINISTRATION; LUNG INFECTION; NEPHROTOXICITY; OSTEOLYSIS; OSTEOPOROSIS; TREATMENT OUTCOME; VOMITING;

EID: 0029862635     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.5650110506     Document Type: Article

References (30)

1. Fleisch H 1991 Bisphosphonates in bone disease. Drugs 42: 919-944.
2. Raue F, Pecherstorfer M 1994 Drug therapy of hypercalcemia due to malignancy. In: Raue F (ed.) Recent Results in Cancer Research: Hypercalcemia of Malignancy. Springer-Verlag, Berlin, pp. 138-160.
3. Kanis JA 1991 Pathophysiology and Treatment of Paget's Disease of Bone. Martin Dunitz, London.
4. Thièbaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, Gobelet C 1994 Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporosis Int 4:76-83.
5. Reid IR, King AR, Alexander CJ, Ibbertson HK 1988 Prevention of steroid-induced osteoporosis with (3-aminohydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1:143-146.
6. Liens D, Delmas PD, Meunier PJ 1991 Long term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 343:953-954.
7. Paterson AHG. Powels TJ, Kanis JA, McCloskey E, Hanson J, Ashley S 1993 Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65.
8. Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F 1983 Renal failure associated with intravenous bisphosphonates. Lancet 1:471.
9. Dumon JC, Magritte A, Body JJ 1991 Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone Miner 15:257-266.
10. Francis MD, Slough C 1983 Acute intravenous infusion of disodium dihydrogen (1-hydroxy-ethylidene) diphosphonate: Mechanism of cytotoxicity. J Pharmaceut Sci 73:1097-1100.
11. Mühlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H 1991 BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003-1011.
12. Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR, Thürlimann B, Tubiana-Hulin M, Steinhauer EU, van Eijkeren M, Huss HJ, Thiébaud D 1996 Randomized phase-II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 14:268-276.
13. O'Rourke NP, McCloskey EV, Vasikaran S, Eyres K, Fern D, Kanis JA 1994 Effective treatment of malignant hypercalcemia with a single intravenous infusion of clodronate. Br J Cancer 67:560-563.
14. Body JJ, Dumon JC 1994 Treatment of tumor-induced hypercalcaemia with the bisphosphonate pamidronate: Dose-response relationship and influence of the tumour type. Ann Oncol 5:359-363.
15. Portale AA 1990 Blood calcium, phosphorus and magnesium. In: Favus MJ (ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Lippincott-Raven Publishers. Philadelphia, pp. 62-64.
16. Jelliffe RW 1973 Creatinine clearance: bedside estimates. Ann Intern Med 79:604-605.
17. Scharla S, Schmidt-Gayk H, Reichel H, Mayer E 1984 A sensitive and simplified radioimmunoassay for 1,25-dihydroxyvitamin D3. Clin Chim Acta 142:325-338.
18. Black D, Duncan A, Robins SP 1988 Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 169:197-203.
19. Robins SP, Stewart P, Astbury C, Bird HA 1986 Measurement of the crosslink compound pyridinoline in urine as an index of collagen degradation. Ann Rheum Dis 45:969-973.
20. Bonjour JP, Philippe J, Bisetti A, Rizzoli R, Jung A, Rosini S, Kanis JA 1988 Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone 9:123-130.
21. Pecherstorfer M, Zimmer-Roth I, Schilling T, Woitge HW, Schmidt H, Baumgartner G, Thiébaud D, Ludwig H, Seibel MJ 1995 The diagnostic value of urinary pyridinium crosslinks of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80:97-103.
22. Walton RJ, Bijvoet OLM 1975 Nomogram for derivation of renal threshold phosphate concentration. Lancet 2:309-310.
23. Body JJ, Magritte A, Seraj F, Sculier JP, Borkowski A 1989 Aminohydroxypropylidene bisphosphonate (APD) treatment for tumour-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions. J Bone Miner Res 4:923-928.
24. Pecherstorfer M, Schilling T, Janisch S, Woloszczuk W, Baumgartner G, Ziegler R, Ogris E 1993 Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med 34:1039-1044.
25. Body JJ, Delmas PD 1992 Urinary pyridinium crosslinks as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 74:471-475.
26. Yates AJP, Percival RC, Gray RES, Atkins RM, Urwin GH, Hamdy NAT, Preston CJ, Beneton MNC, Russell RGG, Kanis JA 1985 Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet 1:1474-1477.
27. Fitton A, McTavish D 1991 Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41:289-318.
28. Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Burckhardt P, Thièbaud D 1996 Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonate treatment in vitro and in patients with malignancy. Bone 18 (in press).
29. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S 1993 Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65.
30. Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ, George S, Zelenakas K, Macerata RS, Seaman JJ 1994 Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. Cancer 74:2949-2955.